Looking for payers you can count on? Then this trio should be right up your alley.
News & Analysis: Gilead Sciences
High yields. Low valuations. But with a couple of downsides to be aware of.
The Belgian biopharma bagged $5.1 billion from its most important partner.
These blue-chip biotechs delivered mixed reports Tuesday.
The big biotech reported stronger revenue thanks primarily to its HIV drug, Biktarvy, and upped its full-year sales guidance.
The three giants in their respective industries posted generally better-than-expected results.
These three healthcare stocks are worth checking out right now. Here's why.
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.
From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.
Gilead Sciences decided to inject $5.1 billion into its R&D partner Galapagos NV over the weekend.